標(biāo)題: Titlebook: Radiotherapy of Liver Cancer; Jinsil Seong Book 2021 Springer Nature Singapore Pte Ltd. 2021 radiation therapy for liver tumors.radiothera [打印本頁] 作者: Agoraphobia 時間: 2025-3-21 18:45
書目名稱Radiotherapy of Liver Cancer影響因子(影響力)
書目名稱Radiotherapy of Liver Cancer影響因子(影響力)學(xué)科排名
書目名稱Radiotherapy of Liver Cancer網(wǎng)絡(luò)公開度
書目名稱Radiotherapy of Liver Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Radiotherapy of Liver Cancer被引頻次
書目名稱Radiotherapy of Liver Cancer被引頻次學(xué)科排名
書目名稱Radiotherapy of Liver Cancer年度引用
書目名稱Radiotherapy of Liver Cancer年度引用學(xué)科排名
書目名稱Radiotherapy of Liver Cancer讀者反饋
書目名稱Radiotherapy of Liver Cancer讀者反饋學(xué)科排名
作者: LUCY 時間: 2025-3-21 23:49 作者: fixed-joint 時間: 2025-3-22 03:59 作者: Pulmonary-Veins 時間: 2025-3-22 08:35
Bo Hyun Kim,Joong-Won Parkcer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima978-3-642-16483-5作者: Aromatic 時間: 2025-3-22 09:36 作者: 防止 時間: 2025-3-22 14:16 作者: milligram 時間: 2025-3-22 17:11 作者: 惡名聲 時間: 2025-3-23 00:28
Pablo Munoz-Schuffenegger,Teo Stanescu,Laura A. Dawsoncer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima978-3-642-16483-5作者: 我說不重要 時間: 2025-3-23 04:07 作者: crumble 時間: 2025-3-23 09:33 作者: deface 時間: 2025-3-23 10:34
Gi Hong Choicer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima978-3-642-27841-9作者: paradigm 時間: 2025-3-23 16:15 作者: fodlder 時間: 2025-3-23 19:27
fields. This work has come to fruition by making use of the expert academic input from the extraordinarily rich population of current and past editorial board members and section editors of and contributors to the Journal of Business Ethics..978-3-319-23514-1作者: PACT 時間: 2025-3-23 22:51
Victor Ho-Fun Lee,Anne Wing-Mui Leeal cancer science, with translational research increasingly becoming a new paradigm in cancer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima作者: 遭受 時間: 2025-3-24 02:23
Jun Yong Parkal cancer science, with translational research increasingly becoming a new paradigm in cancer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima作者: 有其法作用 時間: 2025-3-24 09:03 作者: 無辜 時間: 2025-3-24 11:35
al cancer science, with translational research increasingly becoming a new paradigm in cancer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima作者: PRO 時間: 2025-3-24 18:50
Naoko Sanuki,Atsuya Takeda,Yuichiro Tsurugaial cancer science, with translational research increasingly becoming a new paradigm in cancer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima作者: mechanical 時間: 2025-3-24 20:57 作者: Foolproof 時間: 2025-3-25 00:51
Sang Min Yoonal cancer science, with translational research increasingly becoming a new paradigm in cancer research. In particular, new approaches to both .Personalized Cancer Medicine. and .Targeted Therapies. have made promising progress. While the Second Edition featured scholarly contributions from approxima作者: anachronistic 時間: 2025-3-25 06:08 作者: 獨白 時間: 2025-3-25 08:50 作者: Trochlea 時間: 2025-3-25 13:40
Principle of Cancer Radiotherapyiation technologies and motion management devices, radiation therapy can now be safely delivered to liver tumors. Further radiation dose escalation in the form of hypofractionated stereotactic body radiation therapy (SBRT) is also now feasible, which delivers a high dose of radiation to the tumors w作者: 同時發(fā)生 時間: 2025-3-25 17:48
Radiobiology of the Livero quantify liver function changes following RT. Other more interventional laboratory measures that have been investigated to measure liver function include Indocyanine green (ICG) and HepQuant SHUNT test that require administration of ICG or cholate and measuring their clearance rates. Potential bio作者: acetylcholine 時間: 2025-3-25 21:51
Imaging Anatomy for the Radiation Oncologistartifacts to ensure that the entire wall is included. Imaging features of the arterioportal shunt, malignant portal vein thrombosis, intraductal growing hepatocellular carcinoma, intrahepatic metastasis, and viable tumor after locoregional treatment are also summarized in this chapter because they c作者: 共同給與 時間: 2025-3-26 02:51 作者: CLASH 時間: 2025-3-26 07:59 作者: FIR 時間: 2025-3-26 11:08 作者: 任命 時間: 2025-3-26 15:03 作者: 多余 時間: 2025-3-26 18:03
Therapeutic Guidelines for Patients with Liver Cancer from the Perspective of Radiation Oncologists作者: 壓迫 時間: 2025-3-26 23:32 作者: Bureaucracy 時間: 2025-3-27 04:54 作者: 腫塊 時間: 2025-3-27 08:24
https://doi.org/10.1007/978-981-16-1815-4radiation therapy for liver tumors; radiotherapy strategy; ablative radiotherapy; adjuvant radiotherapy作者: athlete’s-foot 時間: 2025-3-27 10:16 作者: NEXUS 時間: 2025-3-27 16:42 作者: NAIVE 時間: 2025-3-27 21:05
Definitive Radiotherapy for Locally Advanced Hepatocellular Carcinomaeatments has increasingly been used to reverse the situation. Even in patients with HCC having MVI, the reported response rates held promise with regard to reducing the size of vascular invasion and improving the patients’ outcomes after radiotherapy. Here, we summarize previous studies and recent updates of radiotherapy for HCC having MVI.作者: Immunotherapy 時間: 2025-3-27 22:20 作者: 吹牛需要藝術(shù) 時間: 2025-3-28 04:16 作者: jabber 時間: 2025-3-28 07:14
Neoadjuvant Radiotherapy Converting to Curative Resectionwith RT because the aim of RT and timing of liver resection differ between the two approaches. In this chapter, the roles of neoadjuvant and downstaging RT in treating locally advanced HCC are investigated through a review of the literature.作者: LIMN 時間: 2025-3-28 12:39
Principle of Cancer Radiotherapyatients are cured of their cancer by radiotherapy as part of their anticancer treatment. Radiotherapy kills cancer by the use of ionizing radiation which causes permanent and irreversible double-strand DNA breaks in cancer cells leading to cell death. Unfortunately, it can also kill normal cells lea作者: IDEAS 時間: 2025-3-28 17:01
Radiobiology of the Liveration-induced liver disease (RILD) remains a major limitation of RT. The pathophysiology, diagnosis, and treatment of RILD are discussed in this chapter. Classic RILD manifests with hepatomegaly, anicteric ascites, and thrombocytopenia, and alkaline phosphatase elevated out of proportion to other li作者: 易于出錯 時間: 2025-3-28 21:31 作者: 鈍劍 時間: 2025-3-28 23:06 作者: defeatist 時間: 2025-3-29 06:31
Antiviral Therapy in Liver Cancerction, respectively. Antiviral therapy using nucleos(t)ide analogs (NA) reduces HCC occurrence and recurrence in HBV-related HCC. NA therapy also improves overall survival by preventing liver function deterioration and decompensation. Indefinite antiviral therapy is recommended for most patients wit作者: FLIC 時間: 2025-3-29 09:53 作者: 發(fā)誓放棄 時間: 2025-3-29 14:58 作者: 反應(yīng) 時間: 2025-3-29 18:54
Image-Guided Radiotherapydoses of RT safely while respecting the radiation dose limits of numerous normal tissues in the upper abdomen, including the liver itself. Challenges to the routine use of RT to treat hepatic malignancies include the low whole liver tolerance to RT and the proximity of liver tumors to other organs a作者: 愛好 時間: 2025-3-29 21:39
Particle Beam Radiotherapyf HCC by particle therapy is expected to be 85–90% at 3?years and 80–90% at 5?years. Overall survival rate is expected to be 55–65% at 2?years and 20–50% at 5?years. The prognostic factors for survival considered are hepatic function and number and size of tumors..Adverse events due to particle ther作者: 無法破譯 時間: 2025-3-30 00:19 作者: Dislocation 時間: 2025-3-30 04:59 作者: Individual 時間: 2025-3-30 10:58
Transarterial Chemoembolization Plus External Beam Radiotherapyccess with TACE, treated tumors can be revascularized and retreated. When repeated many times, TACE often loses its efficacy and patients enter the state of TACE failure/refractoriness. Radiotherapy (RT) has been investigated as a component of combined treatment to compensate for the limitations of 作者: 可以任性 時間: 2025-3-30 16:26
Definitive Radiotherapy for Locally Advanced Hepatocellular Carcinomaf HCC through the vasculature, decreased portal blood flow to the uninvolved liver, deterioration of hepatic function, and sometimes increased sudden death risk. Although systemic therapies are the current standard treatment in this advanced HCC, radiotherapy with or without combined locoregional tr作者: 流眼淚 時間: 2025-3-30 18:01
Neoadjuvant Radiotherapy Converting to Curative ResectionEven though assessment of the resectability of HCC is still a controversial issue, neoadjuvant RT should be differentiated from downstaging treatment with RT because the aim of RT and timing of liver resection differ between the two approaches. In this chapter, the roles of neoadjuvant and downstagi作者: 歹徒 時間: 2025-3-30 23:03 作者: 犬儒主義者 時間: 2025-3-31 02:54
